ClinicalTrials.gg
RecruitingNCT05779787COMFORTUpdated Apr 16, 2026

COronary Re-engageMent aFter randOm NavitoR alignmenT (COMFORT STUDY)

An observational study in Aortic Valve Stenosis and Transcatheter Aortic Valve Replacement, sponsored by Niguarda Hospital. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Niguarda Hospital · Observational

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 118 studies in Aortic Valve Stenosis with a site in Italy — 39 open to participants now, 54 under way, 1 of them phase 3. Aortic Valve Stenosis · Italy.

Planned enrollment
64th of 71
100 · median 500
Started
2023
with 9 others
Observational
71 of 118
21 open now
Primary completion
2027-02
later than 32 of 53 live
Registered
86th of 118
by date

Among the 118 studies in Aortic Valve Stenosis with a site in Italy, this one is the 64th largest by planned enrollment of the 71 observational ones that give a count, is one of 10 that started in 2023, is one of 71 observational ones, reaches primary completion later than 32 of the 53 other live ones, and was the 86th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

39 of the 118 studies in Aortic Valve Stenosis with a site in Italy are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Aortic Valve Stenosis with a site in Italy, or all of them as a file.
02

Study summary

Whereas PCI before TAVR was previously recommended despite its uncertain prognostic role, recent data underline the possibility of a postponed coronary intervention using a commissural alignment technique. This approach allows easy coronary re-engagement through the valve stent frame with a trade off paid of procedure complexity.

Considering the prevalence of coronary artery disease (CAD) and the increasing percentage of younger patients treated with TAVI, investigate whether a simpler procedure with random implantation of Navitor valve is not inferior in terms of coronary re-access, is required The key point of the project will be the evaluation of the feasibility of coronary re-engagement after a Navitor valve randomly implanted.

Read the detailed description

Transcatheter Aortic Valve Implantation (TAVI) is recommended by European and American guidelines to treat patients with aortic stenosis regardless of procedural risk (1, 2). In the last decades the increasing percentage of younger patients treated with TAVI, reflect the extensive indications in lower risk setting, highlighting the importance of easy coronary re-engagement after valve implantation. Considering the prevalence and the progression of a pre-existing coronary artery disease (CAD), the timing of coronary intervention should be accurate selected (3) addressing the percentage of unplanned percutaneous coronary intervention (PCI) after TAVI (4). In fact, while PCI before TAVR was previously recommend despite the uncertain prognostic role (5), recent data remarks the possibility of a postponed coronary intervention using a commissural alignment technique (6) that allows a predictable stent frame position in the sinus of Valsalva (7). Moreover, following the emerging concept of easy re-access, only a few types of prostheses have been shown to have an high degree of stent position predictability after implantation, leading to a limited option in terms of prosthesis choice. Furthermore, to achieve the best results with commissural alignment technique, accurate procedure planning and operator's expertise are required in order to properly manage the valve specific orientation in the aorta with consequent increase in time, radiation and procedure complexity.

However, geometry of the stent frame (height and size) and the anatomical characteristics of patients have to be enlisted as contributory factors to difficult coronary re-engagement and need to be evaluate in order to establish the feasibility of the re-access after TAVR.

The investigators' findings could provide data regarding the non-inferiority rate of coronary cannulation after a simpler procedure with Navitor implantation without alignment technique. Due to these results, the valves portfolio available in patients with coronary artery disease that needed PCI after TAVR, could be larger and various allowing the best protheses choice according to the patient's anatomy and operator's expertise. Finally, knowing the predictors of difficult re-engagement for both types of valves, regardless of implantation technique, could be interesting for an even more valve tailored approach.

The purpose of this study is to investigate the feasibility of coronary re-engagement after randomly (not aligned) Navitor implantation, as already perform in current clinical practice, due to a lower predictable orientation of this type of valve.

03

Conditions studied

  • Aortic Valve Stenosis
  • Transcatheter Aortic Valve Replacement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive patients with severe aortic stenosis diagnosed according to ESC guidelines, undergoing transcatheters aortic valve replacement with Navitor valve randomly implanted or Acurate Neo with commisural alignment technique

Eligibility criteria

Patients to be included in this registry should have all the following criteria:

1. Severe, symptomatic aortic stenosis with an indication to TAVI

Exclusion criteria and definition

Patients excluded in this registry should have all the following criteria:

  1. Valve in Valve procedure
  2. Hemodynamical instability
  3. TAVR performed from other access (not femoral)
  4. No-CT Planned TAVR
  5. TAVR performed with Chimney Technique
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • TAVR performed with commissural alignment technique (Aligned Group)

    Patients with severe aortic stenosis undergoing TAVR procedure performed with commissural alignment technique. We consider in this groups only the Accurate and Accurate Neo 2 Valve which are the first choice due to the best stent frames position predictability with this technique

    Procedure: TAVR Aligned · Procedure: TAVR Random

  • TAVR performed with random implantation of Navitor valve (Random Group)

    Patients with severe aortic stenosis undergoing TAVR procedure performed with random implantation of Navitor Valve

    Procedure: TAVR Aligned · Procedure: TAVR Random

Interventions

  • ProcedureTAVR Aligned

    Investigate the feasibility of coronary re-engagement after commissural alignment technique in terms of success rate (%) and procedure complexity taking into account radiations, time and contrast used.

  • ProcedureTAVR Random

    TAVR Random Feasibility comparison of coronary re-engagement between the randomly implanted Navitor valve (unaligned) and the others implanted with the commissural alignment technique in terms of success rate (%) and complexity of the procedure, taking into account radiation, time and contrast used

06

What researchers measure

Primary outcomes

  1. Coronary re-access after TAVR procedure

    Re-engagement of LMCA and RCA after valve implantation is defined as selective cannulation and subsequent selective angiography. All others type of re-engagement will be classify as "non selective". We will stratify also the modality of re-cannulation in relation to the position of the valves' stent struts as "above", "across" and "behind".

    Time frame: During procedure

Secondary outcomes

  1. Total Implant Time

    Total time required for valve implantation. We count the time from the alignment in the aorta to the end of valve opening (Alignment Fluoroscopy time + Implantation Fluoroscopy time).

    Time frame: During procedure

  2. Total Implant Fluoroscopy Time

    Total Fluoroscopy time required for valve implantation. We count the time from the alignment in the aorta to the end of valve opening (Alignment time + Implantation time).

    Time frame: During procedure

  3. Total Implant Radiations

    Total Radiations required for valve implantation. We count the radiations used from the alignment in the aorta to the end of valve opening (Alignment time + Implantation time).

    Time frame: During procedure

  4. Total Implant Contrast

    Total Contrast required for valve implantation

    Time frame: During procedure

  5. Alignment Radiation

    Radiation required for commissural alignment

    Time frame: During procedure

  6. Alignment Fluoroscopy Time

    Fluoroscopy time required for commissural alignment

    Time frame: During procedure

  7. Implant Radiation

    Radiation required for valve implantation

    Time frame: During procedure

  8. Implant Fluoroscopy Time

    Fluoroscopy time required for valve implantation

    Time frame: During procedure

  9. Implant Contrast

    Contrast required for valve implantation

    Time frame: During procedure

  10. Re-Engagement Radiation

    Radiation required for re-engagement

    Time frame: During procedure

  11. Re-Engagement Fluoroscopy Time

    Fluoroscopy time required for coronary re-engagement

    Time frame: During procedure

  12. Re-Engagement Contrast used

    Contrast required for coronary re-engagement

    Time frame: During procedure

  13. Re-Engagement Time

    Time required for coronary re-engagement

    Time frame: During procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Feb 2027, 48 months after the start.

Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 48 months is close to that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2023
First posted
Mar 22, 2023
StartActual
Feb 15, 2023
Primary completionEst.
Feb 15, 2027
CompletionEst.
May 15, 2027
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05779787
Lead sponsor
Niguarda Hospital
Responsible party
Sponsor
First posted
Mar 22, 2023
Start date
Feb 15, 2023
Primary completion
Feb 15, 2027 (estimated)
Completion
May 15, 2027 (estimated)
Last update
Apr 16, 2026

Study contacts

Giuseooe Esposito, MD
Contact
giuseppe.esposito@yahoo.com
+393278393131

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion